Portolano Cavallo

Life Sciences

Blog

Feed intended for particular nutritional purposes: in the EU Official Journal the Commission Regulation (EU) 2020/354, establishing a list of intended uses of feed for particular nutritional purposes and repealing the previous Directive 2008/38/EC
11 Feb 20
Medicine and medical device e-commerce: regulatory restrictions and opportunities
More and more healthcare and pharmaceutical companies are entering the world of e-commerce.
11 Feb 20
EDPS: clarification on data protection and scientific research
On January 6, 2020, the European Data Protection Supervisor (EDPS) issued a preliminary opinion on data protection and scientific research, in which it provided clarification on the application of data protection rules established by the General Data Protection Regulation (GDPR) and Regulation No. 2018/1725 with regard to scientific research.
10 Feb 20
Early lessons from the ECJ on access to documents included in a marketing authorization dossier
On January 22, 2020, the European Court of Justice (ECJ) issued its first rulings regarding access to European Union documents submitted as part of a request for marketing authorization (MA) for medicinal products (C-175/18 P, PTC Therapeutics International v. EMA; C-178/18 P, MSD Animal Health Innovation and Intervet International v. EMA).
7 Feb 20
Traditional herbal medicinal products and nutritional supplements: criteria of distinction
With judgment No. 14408 of December 13, 2019, the Administrative Court of the Lazio Region provided clarification on the distinction between traditional herbal medicinal products and nutritional supplements.
7 Feb 20
Venture capital watch: an overview of 2019 investments
We recently attended the country-focused seminar Healthcare: Italy on the Move 2020 during the weeklong J.P. Morgan Annual Healthcare Conference in San Francisco.
Welcome to the Portolano Cavallo Life Sciences blog focusing on legal development and key legal issues affecting the Life Sciences-Healthcare industry.
...
Read more
Our highly-ranked team of professionals will provide news, insights and multidisciplinary commentary on the hottest and most recent regulatory, transactional and contentious aspects of the pharmaceutical, bio-tech, med-tech, food supplement and healthcare world with an eye on its digital transformation and technological developments.

This blog will be a place for focusing on digital health, telemedicine and artificial intelligence, as well as more traditional topics: from the protection of intellectual properties to performance of clinical trials, from the market access to advertising and competition issues, from internal and criminal investigations to M&A and Venture Capital transactions.

Close
October 6, 2023
CBD products: the Administrative Court suspended until October 24 the recent Decree of the Italian Ministry of Health listing cannabidiol for oral use among narcotic drugs, due to the lack o...
October 4, 2023
The Guidelines for regulating contractual relations between universities and research institutes and private sponsors were adopted by the relevant Italian Ministries following the amendment ...
September 21, 2023
CBS products: from September 20th, compositions for oral administration of cannabidiol obtained from Cannabis sativa extracts shall be considered as narcotic drugs in Italy, as they have bee...
July 27, 2023
Payback on medical devices: Italian government announces extension of payment deadline to October 30, 2023
July 21, 2023
On July 21, 2023, the Italian Ministry of Health published new guidelines on health advertising of self-medication drugs (OTC) and non-prescription drugs (SOP), including advertising on new ...
Search by...
Search
Follow us on
Follow us on